Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

Alpha1-antitrypsin inhibits angiogenesis and tumor growth.

Huang H, Campbell SC, Nelius T, Bedford DF, Veliceasa D, Bouck NP, Volpert OV.

Int J Cancer. 2004 Dec 20;112(6):1042-8.

2.

Pigment epithelium-derived factor regulates the vasculature and mass of the prostate and pancreas.

Doll JA, Stellmach VM, Bouck NP, Bergh AR, Lee C, Abramson LP, Cornwell ML, Pins MR, Borensztajn J, Crawford SE.

Nat Med. 2003 Jun;9(6):774-80. Epub 2003 May 12.

PMID:
12740569
3.

Inducer-stimulated Fas targets activated endothelium for destruction by anti-angiogenic thrombospondin-1 and pigment epithelium-derived factor.

Volpert OV, Zaichuk T, Zhou W, Reiher F, Ferguson TA, Stuart PM, Amin M, Bouck NP.

Nat Med. 2002 Apr;8(4):349-57.

PMID:
11927940
4.

Inhibition of tumor growth by systemic treatment with thrombospondin-1 peptide mimetics.

Reiher FK, Volpert OV, Jimenez B, Crawford SE, Dinney CP, Henkin J, Haviv F, Bouck NP, Campbell SC.

Int J Cancer. 2002 Apr 10;98(5):682-9.

5.

Thrombospondin-1, vascular endothelial growth factor and fibroblast growth factor-2 are key functional regulators of angiogenesis in the prostate.

Doll JA, Reiher FK, Crawford SE, Pins MR, Campbell SC, Bouck NP.

Prostate. 2001 Dec 1;49(4):293-305.

PMID:
11746276
6.

The role of hypoxia and p53 in the regulation of angiogenesis in bladder cancer.

Reiher FK, Ivanovich M, Huang H, Smith ND, Bouck NP, Campbell SC.

J Urol. 2001 Jun;165(6 Pt 1):2075-81.

PMID:
11371931
7.

Smad4/DPC4-mediated tumor suppression through suppression of angiogenesis.

Schwarte-Waldhoff I, Volpert OV, Bouck NP, Sipos B, Hahn SA, Klein-Scory S, Lüttges J, Klöppel G, Graeven U, Eilert-Micus C, Hintelmann A, Schmiegel W.

Proc Natl Acad Sci U S A. 2000 Aug 15;97(17):9624-9.

8.

Pigment epithelium-derived factor: a potent inhibitor of angiogenesis.

Dawson DW, Volpert OV, Gillis P, Crawford SE, Xu H, Benedict W, Bouck NP.

Science. 1999 Jul 9;285(5425):245-8.

9.

Keratinocyte growth factor induces angiogenesis and protects endothelial barrier function.

Gillis P, Savla U, Volpert OV, Jimenez B, Waters CM, Panos RJ, Bouck NP.

J Cell Sci. 1999 Jun;112 ( Pt 12):2049-57.

10.

Three distinct D-amino acid substitutions confer potent antiangiogenic activity on an inactive peptide derived from a thrombospondin-1 type 1 repeat.

Dawson DW, Volpert OV, Pearce SF, Schneider AJ, Silverstein RL, Henkin J, Bouck NP.

Mol Pharmacol. 1999 Feb;55(2):332-8.

PMID:
9927626
12.

Inhibition of angiogenesis by interleukin 4.

Volpert OV, Fong T, Koch AE, Peterson JD, Waltenbaugh C, Tepper RI, Bouck NP.

J Exp Med. 1998 Sep 21;188(6):1039-46.

13.

A human fibrosarcoma inhibits systemic angiogenesis and the growth of experimental metastases via thrombospondin-1.

Volpert OV, Lawler J, Bouck NP.

Proc Natl Acad Sci U S A. 1998 May 26;95(11):6343-8.

14.

Molecular mediators of angiogenesis in bladder cancer.

Campbell SC, Volpert OV, Ivanovich M, Bouck NP.

Cancer Res. 1998 Mar 15;58(6):1298-304.

15.

Effects of thrombospondin-1 on disease course and angiogenesis in rat adjuvant-induced arthritis.

Koch AE, Szekanecz Z, Friedman J, Haines GK, Langman CB, Bouck NP.

Clin Immunol Immunopathol. 1998 Feb;86(2):199-208.

PMID:
9473383
16.

CD36 mediates the In vitro inhibitory effects of thrombospondin-1 on endothelial cells.

Dawson DW, Pearce SF, Zhong R, Silverstein RL, Frazier WA, Bouck NP.

J Cell Biol. 1997 Aug 11;138(3):707-17.

17.

The angiogenic switch in hamster buccal pouch keratinocytes is dependent on TGFbeta-1 and is unaffected by ras activation.

Lingen MW, DiPietro LA, Solt DB, Bouck NP, Polverini PJ.

Carcinogenesis. 1997 Feb;18(2):329-38.

PMID:
9054625
18.

Inhibition of angiogenesis in human glioblastomas by chromosome 10 induction of thrombospondin-1.

Hsu SC, Volpert OV, Steck PA, Mikkelsen T, Polverini PJ, Rao S, Chou P, Bouck NP.

Cancer Res. 1996 Dec 15;56(24):5684-91.

19.

Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats.

Volpert OV, Ward WF, Lingen MW, Chesler L, Solt DB, Johnson MD, Molteni A, Polverini PJ, Bouck NP.

J Clin Invest. 1996 Aug 1;98(3):671-9.

20.
21.
22.
23.

Influence of a hamster tumor suppressor gene on transformation by viral and cellular oncogenes.

Benton BK, Volpert OV, Bouck NP.

Carcinogenesis. 1993 Jun;14(6):1209-14.

PMID:
8389673
24.

Transformation of NIH/3T3 to anchorage independence by H-ras is accompanied by loss of suppressor activity.

Tolsma SS, Cohen JD, Ehrlich LS, Bouck NP.

Exp Cell Res. 1993 Apr;205(2):232-9.

PMID:
8482334
25.

Localization of the angiogenesis inhibitor thrombospondin in human synovial tissues.

Koch AE, Friedman J, Burrows JC, Haines GK, Bouck NP.

Pathobiology. 1993;61(1):1-6.

PMID:
8216817
26.

Sister chromatid exchange analysis of human cells exposed to diagnostic levels of ultrasound.

Martin AO, Madsen EL, Dyer AR, White L, Bouck NP, Sabbagha RE, Hermanoff M, Chen JM, Ludtke LJ.

J Ultrasound Med. 1991 Dec;10(12):665-70.

PMID:
1766035
27.

Diagnostic ultrasound is unable to enhance the rate of neoplastic transformation in cultured mammalian cells.

Tolsma SS, Madsen EL, Chmiel J, Martin AO, Bouck NP.

J Ultrasound Med. 1991 Nov;10(11):637-42.

PMID:
1811082
28.

Method of cavitation-suppressed exposure of cells and explant mouse embryos to clinical real-time and pulsed Doppler ultrasound.

Madsen EL, Frank GR, Macdonald MC, Martin AO, Bouck NP, Iannaccone PM.

J Ultrasound Med. 1991 Nov;10(11):629-36. Review.

PMID:
1811081
29.

Assay and purification of naturally occurring inhibitor of angiogenesis.

Polverini PJ, Bouck NP, Rastinejad F.

Methods Enzymol. 1991;198:440-50. No abstract available.

PMID:
1857235
30.

A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin.

Good DJ, Polverini PJ, Rastinejad F, Le Beau MM, Lemons RS, Frazier WA, Bouck NP.

Proc Natl Acad Sci U S A. 1990 Sep;87(17):6624-8.

31.

Effect of a naturally occurring inhibitor of angiogenesis on neovascularization in vivo.

Holland JW, Good DJ, Bouck NP, Polverini PJ.

Northwest Dent Res. 1990 Spring;2(1):6-8. No abstract available.

PMID:
1698393
32.

Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene.

Rastinejad F, Polverini PJ, Bouck NP.

Cell. 1989 Feb 10;56(3):345-55.

PMID:
2464438
33.

Loss of cancer suppressors, a driving force in carcinogenesis.

Bouck NP, Benton BK.

Chem Res Toxicol. 1989 Jan-Feb;2(1):1-11. Review. No abstract available.

PMID:
2519224

Supplemental Content

Loading ...
Support Center